Abnormal echocardiographic findings after COVID-19 infection: a multicenter registry

Sebastián García-Zamora1 · José M. Picco2 · Augusto J. Lepori3 · Marcela I. Galello4 · Ariel K. Saad5 · Miguel Ayón6 · Nancy Monga-Aguilar7 · Issam Shehadeh8 · Carlos F. Manganillo9 · Cintia Izaguirre10 · Luciano N. Fallabrino11 · Matias Clavero12 · Flavia Mansur2 · Sebastián Ghibaudo13 · Daniela Sevilla5,10 · Cesar A. Cado6 · Mauricio Priotti1 · Kiera Liblik14 · Natalio Gastaldello5,7 · Pablo M. Merlo5,7

Received: 31 March 2022 / Accepted: 29 July 2022 / Published online: 13 August 2022
© The Author(s), under exclusive licence to Springer Nature B.V. 2022

Abstract

The Coronavirus Disease 2019 (COVID-19) pandemic has transformed health systems worldwide. There is conflicting data regarding the degree of cardiovascular involvement following infection. A registry was designed to evaluate the prevalence of echocardiographic abnormalities in adults recovered from COVID-19. We prospectively evaluated 595 participants (mean age 45.5 ± 14.9 years; 50.8% female) from 10 institutions in Argentina and Brazil. Median time between infection and evaluation was two months, and 82.5% of participants were not hospitalized for their infection. Echocardiographic studies were conducted with General Electric equipment; 2DE imaging and global longitudinal strain (GLS) of both ventricles were performed. A total of 61.7% of the participants denied relevant cardiovascular history and 41.8% had prolonged symptoms after resolution of COVID-19 infection. Mean left ventricular ejection fraction (LVEF) was 61.0 ± 5.5% overall. In patients without prior comorbidities, 8.2% had some echocardiographic abnormality: 5.7% had reduced GLS, 3.0% had a LVEF below normal range, and 1.1% had wall motion abnormalities. The right ventricle (RV) was dilated in 1.6% of participants, 3.1% had a reduced GLS, and 0.27% had reduced RV function. Mild pericardial effusion was observed in 0.82% of participants. Male patients were more likely to have new echocardiographic abnormalities (OR 2.82, p = 0.002). Time elapsed since infection resolution (p = 0.245), presence of symptoms (p = 0.927), or history of hospitalization during infection (p = 0.671) did not have any correlation with echocardiographic abnormalities. Cardiovascular abnormalities after COVID-19 infection are rare and usually mild, especially following mild infection, being a low GLS of left and right ventricle, the most common ones in our registry. Post COVID cardiac abnormalities may be more frequent among males.

Keywords Echocardiography · COVID-19 · Myocarditis · Diagnostic imaging · Ventricular remodeling · Humans
**Introduction**

In March 2020, a new infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a pandemic, and the disease spread globally [1]. The spectrum of the severity from the novel Coronavirus 19 Disease (COVID-19) ranges from asymptomatic to life-threatening infection where pulmonary involvement predominates, resulting in acute respiratory distress syndrome. However, as information about COVID-19 is further elucidated, cases of cardiovascular involvement have emerged, both during infection and following resolution [2–4]. Further, certain reports have suggested that the majority of patients following COVID-19 infections suffer some kind of cardiac sequelae, regardless of disease severity [5].

The SARS-CoV-2 virus binds to the angiotensin converting enzyme (ACE) II receptor, and it has been theorized that this is the gateway to enter the body [6]. ACE receptors are mainly expressed in the pulmonary alveoli, and the second organ with the highest number of ACE receptors is the heart. Notably, cardiac involvement during COVID-19 infection increases mortality and is correlated with worse outcomes [7–12].

In addition to the clinical manifestations which occur during the acute phase of COVID-19, a significant number of publications have described the persistence of symptoms and alterations after the microbiological recovery from COVID-19 [13–15]. This phenomenon has been called post-COVID syndrome, with a wide prevalence across diverse cohorts [16, 17]. For example, it has been suggested that silent myocardial injury may occur after COVID-19, even among patients who remained asymptomatic during and after acute infection [5, 18].

To date, there are millions of individuals who have recovered from COVID-19 who may be evaluated for long-term cardiovascular sequelae. Additionally, echocardiogram is a widely available and relatively inexpensive method for assessing structural and functional characteristics of the heart. We aimed to explore the prevalence of echocardiographic cardiac abnormalities in ambulatory patients after recovery of a first documented COVID-19 infection.

**Materials and methods**

**Study population**

An observational registry was implemented at nine centers in Argentina and one in Brazil between November 2020 and February 2021, following the first wave of the COVID-19 pandemic in both countries. Adult patients (> 18 years old) who were scheduled to receive a Doppler echocardiogram after a confirmed COVID-19 infection were included, regardless of the reason for the test or the time elapsed since recovery, based on a non probability sampling. Patients with a suboptimal apical ultrasonic window where two or more myocardial segments were not correctly followed for global longitudinal strain (GLS) analysis were excluded from the registry. Similarly, those patients with irregular rhythms or high heart rate where reconstruction of a bull’s eye plot of the left ventricular GLS was not possible were also excluded. We prospectively and consecutively included 595 participants who recovered from a COVID-19 infection with an average age of 45.5 ± 14.9 years, of which 50.8% were female. The majority of patients (82.5%) had the disease at home or in an out-of-hospital center. Of the patients who required hospitalization, 15.3% were in a general ward, 1.9% in intensive care without requiring mechanical ventilation, and 0.3% required mechanical ventilation during the disease. The median time between infection and performance of the echocardiographic study was two months (interquartile range [IQR] 1–3 months). The minimum and maximum ranges between the epidemiological discharge of the patients and the echocardiographic examination was 15 days and nine months, respectively (see Appendix Figure S1).

**Trial protocol**

A case report form was developed in order to collect demographic data, pathological personal history, month in which COVID-19 infection was diagnosed, and severity of the disease. All the echocardiographic studies were carried out with General Electric echocardiography machines (see Appendix Table S1) with an established protocol. All examinations were performed by echocardiographers with at least two years of experience in the routine performance of GLS. In order to reduce the interobserver and the intervendor variability due to the software used, a single commercial brand was used, which previously demonstrated the greatest consistency between the measurements [19, 20].

**Cardiovascular imaging**

The diameters of the left ventricles were obtained in two dimensions (2D) in the left parasternal long axis [21]. The right ventricular (RV) diameter was obtained in the apical four-chamber view at the level of the tricuspid annulus. Pulsed Doppler was performed in the left ventricular inlet tract at the level of the mitral free edge to determine ventricular filling pressures, as well as pulsed tissue Doppler in
the lateral mitral annulus to estimate the E/e’ ratio [22]. The size of the left atrium was determined through indexed atrial volume, performed in four and two apical chambers [21]. Analysis of myocardial deformation from the left ventricle was performed by automatic 2D GLS according to standard recommendations [23]. Ventricular-volume, left ventricular ejection fraction (LVEF), and GLS parameters were determined by automatic endomyocardial edge detection with the least possible intervention by the operator (automatic functional imaging: AFI). The RV function was assessed by visual inspection, the tricuspid annular plane systolic excursion (TAPSE), and the myocardial deformation (strain) which was measured in a RV-focused apical four-chamber view, excluding the interventricular septum [24, 25].

For the GLS analysis of both ventricles, a visual assessment of the 2D imaging tracking was made prior to the analysis. A manual correction of the endocardial borders was allowed to guarantee an appropriate monitoring of all analyzed segments. The software used was the one already installed in each ultrasound machine, which in all cases performed an analysis of the full myocardial wall [19, 20, 23, 25]. According to the brand and model of the equipment used, a normal GLS value was set for the left ventricle above − 18.0% and for the right ventricle above − 20.0% [19, 20, 25].

Statistical analysis

Continuous variables were reported as means with their standard deviations for normally distributed variables or median and interquartile range (IQR) for non-normally distributed variables. Normality was evaluated using graphic tools (histograms and normal probability plot) and Shapiro–Wilk test. Categorical variables were expressed by absolute values and percentages. For normally distributed variables, the analysis was performed using the Student's t-test. For non-normally distributed variables, the Wilcoxon rank sum test was used. Differences in proportions were evaluated by the Chi Square test or Fisher’s Exact test according to the frequency of expected values.

After excluding participants with previous cardiovascular disease or with any comorbidity, we manually performed a multiple logistic regression model in order to investigate which clinical variables were associated with presenting any abnormality on the echocardiogram. Once the final model was obtained, its predictive capacity was evaluated by constructing a Receiver Operating Characteristic (ROC) curve. A two-tail p-value < 0.05 was considered statistically significant in all cases. STATA version 13.0 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.) was used for the analyses.

Results

Study population and baseline clinical characteristics

The reasons for echocardiographic evaluation included: persisting or new symptoms after disease recovery (61.7%), patient fear of suffering from a cardiac disorder due to COVID (30.5%), and monitoring of pre-existing cardiovascular pathology (7.8%). At the time of the study, 58.2% of the participants were asymptomatic. Among patients who reported symptoms following COVID-19 recovery, the most frequently reported was dyspnea (47.4%), followed by mild symptoms such as asthenia, arterial hypertension or palpitations (32.9%), 12.9% referred chest pain, 6% of patients reported dyspnea and chest pain, and 0.8% reported various other symptoms.

The mean body mass index in the patients was 26.8 ± 4.8 kg/m², and 61.7% of the participants denied any relevant medical history. The most frequent comorbidity was arterial hypertension (28.6%). Table 1 summarizes the characteristics of the included patients.

| Characteristics                      | Overall (n = 595) | Female (n = 302) | Male (n = 293) | “p”   |
|-------------------------------------|------------------|------------------|---------------|-------|
| Body mass index (kg/m²)             | 26.8 ± 4.8       | 26.3 ± 5.3       | 27.4 ± 4.1    | 0.005 |
| Arterial hypertension               | 28.6%            | 23.2%            | 34.1%         | 0.003 |
| Diabetes                            | 6.1%             | 3.3%             | 8.9%          | 0.005 |
| Dyslipidemia                        | 3.5%             | 2.0%             | 5.1%          | 0.046 |
| Smokers                             | 2.5%             | 3.3%             | 2.1%          | 0.180 |
| Former smokers                      | 1.9%             | 1.0%             | 2.7%          | 0.150 |
| Cardiovascular diseases             | 3.0%             | 1.7%             | 4.8%          | 0.036 |
| Valvular diseases                   | 2.0%             | 2.0%             | 2.1%          | 0.593 |
| Other cardiovascular diseases       | 3.5%             | 4.3%             | 2.7%          | 0.376 |
| Non cardiovascular diseases         | 3.9%             | 4.3%             | 3.4%          | 0.573 |
Echocardiographic examination of participants demonstrated a mean left atrial volume of 33.1±13.2 ml/m², and 32.9% of the participants had some degree of left atrial enlargement. The mean LVEF was estimated at 61.0±5.5%, and 3.7% of the participants had a LVEF below 50%. Table 2 summarizes relevant echocardiographic findings.

Among patients with reduced LVEF (3.7%), 50.0% of them denied a relevant medical history and were unaware of this condition. In this subgroup, 90.1% had mildly abnormal LVEF (0.3%) underwent cardiac magnetic resonance (CMR) which confirmed a myocarditis pattern. Abnormal wall motions by visual analysis were detected in 4.4% of the participants. After excluding those with a history of ischemic cardiomyopathy or depressed LVEF, 1.1% of the participants presented abnormal wall motions in the left ventricle. GLS had an average value of −20.6±2.7%, and 12.1% of the participants had a value inferior to −18.0%. After excluding patients with significant cardiovascular or clinical comorbidities, as well as those with ventricular dysfunction at the time of the examination, 5.7% of the participants had a reduced GLS. This finding was more frequent among male participants than female participants (11.1% versus 1.5%, p < 0.001).

Pericardial effusion was observed in 1.2% of the participants, but was mild in all cases. No patient with pericardial effusion presented reduced GLS, while only one of them presented RV free wall GLS less than normal. We found no significant differences in LVEF between symptomatic and asymptomatic patients (61.4% versus 60.6% respectively, p = 0.104). Symptomatic patients showed slightly reduced GLS (−20.3% versus −20.9%, p = 0.012) with a trend

---

**Table 2** Echocardiographic findings according to sex

| Parameter                                             | Overall     | Female     | Male       | “p”   |
|-------------------------------------------------------|-------------|------------|------------|-------|
| Left ventricular diastolic dimension (mm)              | 46.1±4.6    | 44.3±4.1   | 48.0±4.4   | < 0.001|
| Septal thickness (mm)                                 | 9.3±2.8     | 8.6±2.0    | 10.0±3.2   | < 0.001|
| Posterior wall thickness (mm)                          | 8.8±1.5     | 8.1±1.3    | 9.4±1.4    | < 0.001|
| Left ventricular systolic dimension (mm)              | 29.8±5.1    | 28.5±4.2   | 31.1±5.7   | < 0.001|
| Left atrial volume                                    | 33.1±13.2   | 30.7±11.1  | 35.5±14.7  | < 0.001|
| Left atrial:                                           |             |            |            |       |
| Mildly abnormal                                       | 15.1%       | 12.9%      | 17.4%      | 0.001 |
| Moderately abnormal                                   | 6.9%        | 7.0%       | 6.8%       |       |
| Severely abnormal                                     | 10.9%       | 6.6%       | 15.4%      |       |
| Left ventricular end-diastolic volume                  | 79.1±26.9   | 68.7±20.8  | 89.8±28.4  | < 0.001|
| Left ventricular end-systolic volume                   | 34.1±15.6   | 29.4±12.8  | 38.9±16.8  | < 0.001|
| Left ventricular ejection fraction                     | 61.0±5.5    | 61.9±5.7   | 60.2±5.2   | < 0.001|
| Left ventricular ejection fraction                     |             |            |            |       |
| Mildly abnormal (LVEF 40–52 to 54%)                    | 3.0%        | 2.7%       | 3.4%       | 0.541 |
| Moderately abnormal (LVEF 30–39%)                     | 0.7%        | 1.0%       | 0.3%       |       |
| Mitral E/e’ ratio                                     | 7.2±2.3     | 7.3±2.3    | 7.2±2.4    | 0.553 |
| Right ventricular basal diameter (mm)                  | 30.5±6.3    | 28.6±5.3   | 32.5±6.5   | < 0.001|
| TAPSE (mm)                                            | 23.4±3.4    | 23.2±3.3   | 23.7±3.4   | 0.113 |
| Pulmonary artery systolic pressure (mmHg) [n = 329]    | 27.9±5.2    | 27.6±4.8   | 28.3±5.5   | 0.210 |
| Global longitudinal strain (− %)                       | 20.6±2.7    | 21.4±2.6   | 19.9±2.7   | < 0.001|
| RV free wall GLS (− %) [n = 460]                       | 26.0±4.4    | 26.1±4.7   | 25.8±4.2   | 0.462 |

_mm millimeter, LVEF left ventricular ejection fraction, TAPSE tricuspid annular plane systolic excursion, RV right ventricle, GLS global longitudinal strain_
the same direction in the RV free wall GLS (−25.6% versus −26.3%, p = 0.103).

In Table 3 we summarized the echocardiographic abnormalities in patients with and without pre-existing comorbidities.

Globally, 8.2% of the participants without prior cardiovascular disease or significant comorbidities had some echocardiographic abnormality (Fig. 1). New echocardiographic abnormalities were more frequent in male patients than female patients (OR 2.82, 95% CI 1.46–5.45, p = 0.002). Conversely, we did not find any relationship between time elapsed from infection to study enrollment (OR 1.11 95% CI 0.93–1.33, p = 0.245), the presence of symptoms (OR 0.97 95% CI 0.51–1.83, p = 0.927), or requiring hospitalization during COVID-19 infection (OR 1.18 95% CI 0.55–2.51, p = 0.671). Through the construction of a ROC curve we were able to detect that age as a single variable had a low predictive value for new abnormalities in the echocardiogram (area under ROC curve of 0.65) (see Appendix Figure S2).

Due to the basal differences of the participants (Table 1), we developed a multivariable logistic regression model to explore the role of male sex to predict any echocardiographic cardiac abnormality irrespective of prior characteristics and comorbidities. Notably, the difference between sexes remains independent and statistically significant after adjusting for severity of the infection, time between COVID-19 disease and echocardiographic examination, presence of symptoms,

---

**Table 3** Echocardiographic abnormalities according to pre-existing comorbidities

| Echocardiographic finding     | Non comorbidities (61.7%; n = 367) | With comorbidities (38.3%; n = 228) | “p”   |
|------------------------------|------------------------------------|------------------------------------|-------|
| Mid-range LVEF              | 2.7% (10)                          | 3.6% (8)                           | 0.572 |
| LVEF below 40%              | 0.3% (1)                           | 1.4% (3)                           | 0.128 |
| Abnormal wall motions in LV | 1.1% (4)                           | 8.8% (20)                          | < 0.001 |
| Reduced GLS (below −18.0%)  | 5.7% (21)                          | 21.1% (48)                         | < 0.001 |
| Dilated RV                  | 1.6% (6)                           | 2.2% (5)                           | 0.630 |
| Reduced RV function         | 0.27% (1)                          | 1.8% (4)                           | 0.074 |
| Reduced RV GLS (n = 460)*   | 3.1% (9)                           | 7.2% (12)                          | 0.060 |
| Pericardial effusion        | 0.82% (3)                          | 1.8% (4)                           | 0.437 |
| PASP (n = 329)              | 27.3 ± 4.5 mmHg                    | 29.0 ± 5.9 mmHg                    | 0.003 |

*For RV a reduced GLS was considered with a value under −20.0%  
LVEF left ventricular ejection fraction, GLS global longitudinal strain, RV right ventricle, PASP Pulmonary artery systolic pressure
age, hypertension, diabetes, dyslipidemia, smokes, cardiovascular diseases, left atrial volume and diastolic function. The estimated OR was 3.72 (95% CI 1.86–7.46, p < 0.001); age was the other independent variable that predicted echocardiographic abnormalities (OR 0.96 95% CI 0.94 – 0.99, p = 0.004).

Discussion

The main findings of our study were: (i) a relatively low rate of echocardiographic abnormalities after a mild COVID-19 infection; (ii) the most frequent alterations were a left ventricular GLS below the normal range, followed by an abnormal RV free wall GLS; (iii) the more severe abnormalities (a moderately reduced LVEF and pericardial effusion) were seen in less than 1% of participants; (iv) any echocardiographic abnormalities were more frequent in male patients irrespective of any other demographic or clinical characteristic.

The COVID-19 pandemic has created an enormous challenge for health systems around the world. The initial demand for the care of acute patients was then compounded by care of individuals affected by sequelae following recovery. Since the first literature emerged about COVID-19, possible cardiovascular involvement has been identified and linked to a worse prognosis [7, 9, 26]. Accordingly, an autopsy study from patients who died of COVID-19 reported that the virus was documented in the cardiac tissue of 61.5% of those studied [26]. Multiple publications have similarly identified the role of echocardiography in detecting cardiovascular abnormalities during the acute phase of the disease, and the prognostic implications of this finding [27–31]. Most of the data suggested that RV and LV strain measured by speckle-tracking were acceptable parameters to predict poor outcomes, including mortality [28–30].

Perhaps the more complex issue is determining the true degree of cardiac involvement in individuals recovered after a COVID-19 infection, and related clinical relevance. An initial study found that 78% of the individuals recently recovered after a COVID-19 infection presented some alteration in the CMR, and 60% presented signs of ongoing myocardial inflammation [5]. This study included only 100 participants and the main imaging findings were alterations in native T2 and T1 mapping. The CMR examination was performed on average 71 days (interquartile range [IQR] 64 to 92 days) after the initial positive test for COVID-19 [5]. In contrast, a case series which evaluated 145 young athletes with CMR on an average of 15 days after being diagnosed with COVID-19 infection found alterations compatible with myocarditis in 1.4% of them [32]. In this series, there were no participants with severe symptoms, and 16.6% of the participants had an asymptomatic infection [32]. A systematic review and meta-analysis of CMR also found a prevalence of myocarditis and late gadolinium enhancement of 14.0% and 20.5%, respectively, in those recovered from COVID-19 [33]. However, they included 890 patients from 16 studies with high heterogeneity, which limits the generalizability of this dataset [34, 35]. Conversely, participants in our registry have characteristics similar to most people recovering from COVID-19 infection.

Previous authors have investigated the cardiac impact of COVID-19 infection after recovery with echocardiography. Moody et al. performed an echocardiographic examination during COVID-19 disease and three months after the first transthoracic echocardiography (TTE) [36]. They included 79 patients, of whom all required hospitalization due to COVID infection, and 80% received mechanical ventilation, with the median hospitalization stay of 32 days. At follow-up, 29% of the participants presented some echocardiographic alteration, the most frequent being right ventricular dysfunction [36]. Similarly, Tungen et al. evaluated 92 adults who required hospitalization in Norwegian hospitals, and performed a TTE three months after infection [37]. Twenty percent of participants required admission to the intensive care unit, and three needed mechanical ventilation. All patients had preserved LVEF, but 6.5% of the participants had reduced left ventricle GLS, with no alternative explanation, similar to our findings [37]. The authors did not observe any right ventricle abnormality and could not find a relationship between echocardiographic abnormalities and the severity of the infection, as in our study [37]. Another study of Baruch et al. with 80 adult patients found that approximately three months after recovery 63% of the participants had some symptoms, but the LVEF of all participants was preserved. However, 25% had a decreased GLS, and 8% had an RV GLS below the normal value [38]. The findings of this late study are more similar to our study. Similar differences can be observed in more recent publications [39–42], with rates of subclinical ventricular in up to one in three hospitalized patients [40]. The most reasonable explanation for the discrepancies observed between series of post COVID-19 patients are the differences in the severity of the patients included in them. Accordingly, our registry is novel because a large proportion of included patients were not hospitalized for infection, allowing the assessment of the impact of a broad spectrum of disease severity. Since the beginning of the pandemic it has been described that around 70–80% of affected individuals have a mild or asymptomatic infection [43, 44]. This proportion is similar to the participants who suffered from a mild infection in our registry. An important issue is that despite the differences between the studies, all of them show that subclinical alterations are the leading form of cardiac post COVID-19 alterations, with overt manifestation being less frequent. Our registry
which is actually a common limitation to all studies based on echocardiographic findings. Furthermore, since most of the participants suffered from a mild viral infection, it is not possible to generalize these findings to all post COVID-19 patients, especially among patients with more severe disease. However, as we pointed out in previous paragraphs, the majority of people who have suffered from COVID-19 experienced a mild or asymptomatic infection. Additionally, we did not have a centralized core laboratory to analyze the biventricular global longitudinal strain. However, all analyses were performed by experienced operators and with the same brand of ultrasound machine (General Electric), which minimizes technical variation, as previously published [19, 20, 23, 25]. Even more, the brand ultrasound machine used in our registry has shown the higher interobserver agreement in prior publications [19, 20]. Another major limitation is the lack availability of confirmatory imaging modalities such as cardiac magnetic resonance. Though, due to the high burden of COVID-19 infection it is impracticable to perform complex imaging on a broad number of patients, particularly following mild disease. Finally, taking into account the relatively short time between the COVID-19 infection and the echocardiographic examination, it is also not possible to know the prevalence of long-term cardiovascular abnormalities. Nonetheless, there is no reason to suspect that new echocardiographic abnormalities will develop in a period of time greater than that of our record.

Despite the aforementioned, this registry had a considerable sample size, and the observations were made in different regions but with socio-demographic and technological equipment similarities, which reinforces their generalizability.

**Conclusion**

Our study suggests that cardiovascular abnormalities after a COVID-19 infection are infrequent and usually mild, even when they are evaluated during the first weeks after recovery from the disease. The most frequent findings were a decrease in the GLS of both the left and the right ventricle, followed by a mild reduction in the LVEF. In contrast, the most clinically significant abnormalities, such a pericardial effusion or a moderately depressed left ventricular ejection fraction were rare.

We found no relationship between echocardiographic abnormalities and the severity of the disease or the time elapsed since recovery. Interestingly, we also did not find a relationship between the presence of symptoms and the echocardiographic abnormalities. Our data also suggest that echocardiographic abnormalities may be more frequent among male patients. Further studies are needed to delineate which patients will develop cardiovascular abnormalities after COVID-19 infection.
Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s10554-022-02706-9.

Author contributions  SGZ, JMP, NG and PMM designed the project. SGZ, JMP and KB wrote the main manuscript text AKS, SOG and MA prepared tables 1-3 AJL, PMM and SOG prepared figure 1. All authors performed data collection & reviewed the manuscript.

Funding  The present study has not received any grants or financial support.

Declarations  Conflict of interest  The authors declare no competing interests.

References

1. Attri D, Siddiqui HK, Lang JP, Naufial V, Morrow DA, Bohula EA (2020) COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. JACC Basic Transl Sci 5(5):518–536. https://doi.org/10.1016/j.jacbts.2020.04.002
2. Haseeb S, Gul EE, Cinier G, Bazoukis G, Alvarez-Garcia J, Garcia-Zamora S et al (2020) Value of electrocardiography in coronavirus disease 2019 (COVID-19). J Electrocardiol 62:39–45. https://doi.org/10.1016/j.jelectrocard.2020.08.007
3. Zeng L, Wang S, Cai J, Sun S, Wang S, Li J et al (2020) Clinical characteristics of COVID-19 with cardiac injury: a systematic review and meta-analysis. Epidemiol Infect 148:e266. https://doi.org/10.1017/S0950268820002587
4. Walker C, Deb S, Ling H, Wang Z (2020) Assessing the elevation of cardiac biomarkers and the severity of COVID-19 infection: a meta-analysis. J Pharm Pharm Sci 23:396–405. https://doi.org/10.18433/jpps31501
5. Punthmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J et al (2020) Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 5(11):1265–1273. https://doi.org/10.1001/jamacardio.2020.3557
6. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A et al (2020) COVID-19 and cardiovascular disease. Circulation 141(20):1648–1655. https://doi.org/10.1161/CIRCULATIONAHA.120.046941
7. Li X, Guan B, Su T, Liu W, Chen M, Bin Waaleed K et al (2020) Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. Heart 106(15):1142–1147. https://doi.org/10.1136/heartjnl-2020-317062
8. Majdidi M, Safavi-Naeini P, Solomon SD, Vardeny O (2020) Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 5(7):831–840. https://doi.org/10.1001/jamacardio.2020.1286
9. Garcia-Zamora S, Lee S, Haseeb S, Bazoukis G, Tse G, Alvarez-Garcia J et al (2021) Arrhythmias and electrophysiographic findings in Coronavirus disease 2019: a systematic review and meta-analysis. Pacing Clin Electrophysiol 44(6):1062–1074. https://doi.org/10.1111/pce.14247
10. Abate SM, Mantefaro B, Nega S, Chekole YA, Basu B, Ali SA et al (2021) Global burden of acute myocardial injury associated with COVID-19: a systematic review, meta-analysis, and meta-regression. Ann Med Surg (Lond) 68:102594. https://doi.org/10.1016/j.amsu.2021.102594
11. Li JW, Han TW, Woodward M, Anderson CS, Zhou H, Chen YD et al (2020) The impact of 2019 novel coronavirus on heart injury: a systematic review and meta-analysis. Prog Cardiovasc Dis 63(4):518–524. https://doi.org/10.1016/j.pcad.2020.04.008
12. Parohan M, Yaghoubi S, Seraji A (2020) Cardiac injury is associated with severe outcome and death in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Eur Heart J Acute Cardiovasc Care 9(6):665–677. https://doi.org/10.1177/2048872620937165
13. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM et al (2021) Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. https://doi.org/10.1016/j.bbi.2021.12.020
14. Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S et al (2022) Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J Med Virol 94(1):253–262. https://doi.org/10.1002/jmv.27309
15. Iqbal FM, Lam K, Sounnderajahl V, Clarke JM, Asfahani H, Darzi A (2021) Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinical Medicine 36:100899. https://doi.org/10.1016/j.eclinm.2021.100899
16. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR et al (2021) Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 4(10):e2128568. https://doi.org/10.1001/jamanetworkopen.2021.28568
17. Gusecka A, Pruc M, Kukula K, Gilis-Malinowska N, Filipiak KJ, Jaguszewski MJ et al (2021) Post-COVID-19 heart syndrome. Cardiol J 28(2):353–354. https://doi.org/10.5603/CJ.a2021.0028
18. Eiros R, Barreiro-Perez M, Martin-Garcia A, Almeida J, Villacorta E, Perez-Pons A et al (2021) Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers. Res Esp Cardiol (Engl Ed). https://doi.org/10.1016/j.rec.2021.10.021
19. Farsalinos KE, Darabah AM, Unlu S, Thomas JD, Badano LP, Voigt JU (2015) Head-to-head comparison of global longitudinal strain measurements among nine different vendors: The EACVI/ASE inter-vendor comparison study. J Am Soc Echocardiogr 28(10):1171–1181. https://doi.org/10.1016/j.echo.2015.06.011
20. Nagata Y, Takeuchi M, Mizukoshi K, Wu VC, Lin FC, Negishi K et al (2015) Intervendor variability of two-dimensional strain using vendor-specific and vendor-independent software. J Am Soc Echocardiogr 28(6):630–641. https://doi.org/10.1016/j.echo.2015.01.021
21. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of cardiovascular imaging. J Am Soc Echocardiogr 28(1):1–39. https://doi.org/10.1016/j.echo.2014.10.003
22. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 29(4):277–314. https://doi.org/10.1016/j.echo.2016.01.011
23. Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R et al (2015) Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr 28(2):183–193. https://doi.org/10.1016/j.echo.2014.11.003
24. Schneider M, Ran H, Aschauer S, Binder C, Mascherbauer J, Lang I et al (2019) Visual assessment of right ventricular function by
echocardiography: how good are we? Int J Cardiovasc Imaging 35(11):2001–2008. https://doi.org/10.1007/s10554-019-01653-2

25. Badano LP, Kolias TJ, Muraru D, Abraham TP, Aurigemma G, Edvardsen T et al (2018) Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/FASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging 19(6):591–600. https://doi.org/10.1093/ehjci/jey042

26. Lindner D, Fitez A, Brauning E, Aleshcheva G, Edler C, Starekova J, Bluemke DA, Bradham WS, Eckhardt LL, Grist Krishnamoorthy P, Croft LB, Ro R, Anastasius M, Zhao W, Khani M, Tavana S, Tabary M, Naseri Kivi Z, Khaheshi I (2021) Prevalence of abnormal cardiac magnetic resonance findings in COVID-19 patients 3 months after hospitalization for COVID-19. J Am Soc Echocardiogr 34(10):1475–1481. https://doi.org/10.1016/j.echo.2021.01.020

27. Jain SS, Liu Q, Raikherkar J, Fried J, Elias P, Poterucha TJ et al (2020) Indications for and findings on transthoracic echocardiography in COVID-19. J Am Soc Echocardiogr 33(10):1278–1284. https://doi.org/10.1016/j.echo.2020.06.009

28. Khani M, Taverna S, Tabary M, Naseri Kivi Z, Khaheshi I (2021) Prognostic implications of biventricular strain measurement in COVID-19 patients by speckle-tracking echocardiography. Clin Cardiol 44(10):1475–1481. https://doi.org/10.1002/clc.23708

29. Rothschild E, Baruch G, Rothstein HR (2008) Reasons for and excuses for avoiding meta-analysis in forest plots. BMJ 337:a2217. https://doi.org/10.1136/bmj.a2217

30. Ioannidis JP, Patsopoulos NA, Rothstein HR (2008) Why most published research findings are false. PLoS Med 5(7):e124. https://doi.org/10.1371/journal.pmed.0050124

31. Tangen J, Aukrust P, Barratt-Due A, Skullstad H, Edvardsen T (2022) Reduced cardiac function by echocardiography in a minority of COVID-19 patients 3 months after hospitalization. J Am Soc Echocardiogr 35(2):243–244. https://doi.org/10.1016/j.echo.2021.10.014

32. Baruch G, Rothschild E, Sadon S, Szekely Y, Lichter Y, Kaplan A et al (2019) Evolution of right and left ventricular function and speckle-tracking echocardiography in patients recovering from coronavirus disease:

33. 85 The International Journal of Cardiovascular Imaging (2023) 39:77–85